The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

被引：1

作者：

Topal, Alper ^{[1
]}

Erturk, Ismail ^{[1
]}

Koseoglu, Caglar ^{[1
]}

Dumludag, Aysegul ^{[1
]}

Kuzu, oemer Faruk ^{[1
]}

Durmaz, Pelin ^{[1
]}

Akdag, Goncagul ^{[2
]}

Keskin, Gul Sema Yildiran ^{[1
]}

Karadurmus, Nuri ^{[1
]}

机构：

[1] Gulhane Res & Training Hosp, Dept Internal Med, Div Med Oncol, Gen Dr Tevfik Saglam Caddesi 1 Etlik, Ankara, Turkiye

[2] Hlth Sci Univ, Kartal Dr Lutfi Kirdar City Hosp, Dept Med Oncol, Istanbul, Turkiye

来源：

CLINICAL GENITOURINARY CANCER | 2024年 / 22卷 / 04期

关键词：

Autologous stem cell transplantation; Salvage therapy; Overall survival; Complete response; ETOPOSIDE; DIAGNOSIS; SURGERY;

D O I：

10.1016/j.clgc.2024.102106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We aimed to analyze response rates, survival, and factors influencing outcomes in patients with ovarian germ cell tumors undergoing HDC and ASCT. Twenty-one patients were included. After HDC + ASCT, CR was observed in 11 patients (52.3%), PR in 3 patients (14.3%). Median PFS and OS were calculated to be 6.0 months and 14.8 months, respectively. Salvage HDC + ASCT is an effective option in ovarian germ cell tumours. Objective: We aimed to investigate response rates, survival analyses and factors affecting survival in patients with relapsed or refractory ovarian germ cell tumours who had previously received multiple lines of treatment, including high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Methods: This study was designed as a cross-sectional, retrospective study. Results: Twenty-one patients were included. After HDC + ASCT, complete response (CR) was observed in 11 patients (52.3%), partial response (PR) in 3 patients (14.3%), stable disease (SD) in 3 patients (14.3%) and progressive disease (PD) in 4 patients (19.1%). TRM was observed in 1 patient. Median followup was 51.7 months. Median PFS and OS after HDC + ASCT were calculated to be 6.0 months and 14.8 months, respectively. Conclusions: Salvage HDC + ASCT is an effective option in the treatment of relapsed/refractory ovarian germ cell tumours, offering the potential for prolonged survival and cure.

引用

页数：9

共 27 条

[1] High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors [J].

Ammakkanavar, Natraj Reddy ;

Matei, Daniela ;

Abonour, Rafat ;

Einhorn, Lawrence H. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :226-U148

[2] Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours [J].

Aykan, Musa Baris ;

Yildiran, Gul Sema ;

Akcan, Ece ;

Acar, Ramazan ;

Erturk, Ismail ;

Karadurmus, Nuri .

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (07) :880-884

[3] Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer [J].

Beyer, J. ;

Albers, P. ;

Altena, R. ;

Aparicio, J. ;

Bokemeyer, C. ;

Busch, J. ;

Cathomas, R. ;

Cavallin-Stahl, E. ;

Clarke, N. W. ;

Classen, J. ;

Cohn-Cedermark, G. ;

Dahl, A. A. ;

Daugaard, G. ;

De Giorgi, U. ;

De Santis, M. ;

De Wit, M. ;

De Wit, R. ;

Dieckmann, K. P. ;

Fenner, M. ;

Fizazi, K. ;

Flechon, A. ;

Fossa, S. D. ;

Germa Lluch, J. R. ;

Gietema, J. A. ;

Gillessen, S. ;

Giwercman, A. ;

Hartmann, J. T. ;

Heidenreich, A. ;

Hentrich, M. ;

Honecker, F. ;

Horwich, A. ;

Huddart, R. A. ;

Kliesch, S. ;

Kollmannsberger, C. ;

Krege, S. ;

Laguna, M. P. ;

Looijenga, L. H. J. ;

Lorch, A. ;

Lotz, J. P. ;

Mayer, F. ;

Necchi, A. ;

Nicolai, N. ;

Nuver, J. ;

Oechsle, K. ;

Oldenburg, J. ;

Oosterhuis, J. W. ;

Powles, T. ;

Rajpert-De Meyts, E. ;

Rick, O. ;

Rosti, G. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :878-888

[4]

BROUN ER, 1994, CANCER, V73, P1716, DOI 10.1002/1097-0142(19940315)73:6<1716::AID-CNCR2820730627>3.0.CO

[5]

2-L

[6] Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) [J].

De Giorgi, U. ;

Richard, S. ;

Badoglio, M. ;

Kanfer, E. ;

Bourrhis, J. H. ;

Nicolas-Virelizier, E. ;

Vettenranta, K. ;

Lioure, B. ;

Martin, S. ;

Dreger, P. ;

Schuler, M. K. ;

Thomson, K. ;

Scarpi, E. ;

Rosti, G. ;

Selle, F. ;

Mangili, G. ;

Lanza, F. ;

Bregni, M. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1910-1916

[7] Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors [J].

De Giorgi, Ugo ;

Casadei, Chiara ;

Bergamini, Alice ;

Attademo, Laura ;

Cormio, Gennaro ;

Lorusso, Domenica ;

Pignata, Sandro ;

Mangili, Giorgia .

CANCERS, 2019, 11 (10)

[8]

Feldman DR, 2015, Urological Oncology Springer, P431

[9] Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era [J].

Hamid, Anis A. ;

Markt, Sarah C. ;

Vicier, Cecile ;

McDermott, Kathleen ;

Richardson, Paul ;

Ho, Vincent T. ;

Sweeney, Christopher J. .

CLINICAL GENITOURINARY CANCER, 2019, 17 (01) :58-+

[10]

Kaur B, 2020, Diagn Histopathol, V26, P289, DOI [10.1016/j.mpdhp.2020.03.006, DOI 10.1016/J.MPDHP.2020.03.006]

← 1 2 3 →